← Leaderboards
Bo R Rueda
Massachusetts General Hospital
$4,953,014
Attributed
$7,460,797
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $744.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,460,797 · 4
By mechanism
R01$7,460,797 · 4
Top collaborators
- Timothy J Cardozo9 shared
- Leslie Ina Gold9 shared
- Kathleen H Burns1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- David Pepin$2,535,692
- Mehmet Toner$56,861,630
Others in their field
Top investigators on “Progesterone”
- William G Barsan · University Of Michigan At Ann Arbor$25,546,111
- Bert W O'Malley · Baylor College Of Medicine$20,446,513
- David W Wright · Virginia Commonwealth University$17,882,898
- Serdar E Bulun · Northwestern University$14,966,619
- Howard N Hodis · University Of Southern California$14,243,539
- Ji-Yong Julie Kim · University Of Illinois At Chicago$13,221,781
Research focus
ProgesteroneEndometriumCell Cycle ProteinsCell ProliferationProteinsEpithelial CellsIn VivoTissuesIn VitroCellsMalignant - DescriptorMalignant NeoplasmsMouse ModelEndometrialNovel StrategiesEndometrial CarcinomaMediatingOncogenesCell CycleGrowthInhibitor/AntagonistEstrogensEventCarcinogenesis
Grant awards (22)
Defining the genomic and biologic impact of LINE-1 activity in fallopian tube epithelial cells$744,575
R01 · FY2025 · CA · contact PI
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer$581,460
R01 · FY2018 · CA
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer$579,879
R01 · FY2017 · CA
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer$60,511
R01 · FY2017 · CA
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer$583,157
R01 · FY2016 · CA
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer$79,392
R01 · FY2016 · CA
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer$586,799
R01 · FY2015 · CA
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer$79,392
R01 · FY2015 · CA
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer$12,996
R01 · FY2015 · CA
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer$639,657
R01 · FY2014 · CA
Cables role in endometrial differentiation and cancer$364,978
R01 · FY2007 · CA · contact PI
Cables role in endometrial differentiation and cancer$375,879
R01 · FY2006 · CA · contact PI
Cables role in endometrial differentiation and cancer$384,925
R01 · FY2005 · CA
Regulation of the sphingomyelin pathway in the CL$299,846
R01 · FY2005 · HD
Cables role in endometrial differentiation and cancer$384,925
R01 · FY2004 · CA
Regulation of the sphingomyelin pathway in the CL$299,846
R01 · FY2004 · HD
Cables role in endometrial differentiation and cancer$384,925
R01 · FY2003 · CA
Regulation of the sphingomyelin pathway in the CL$299,846
R01 · FY2003 · HD
Regulation of the sphingomyelin pathway in the CL$322,346
R01 · FY2002 · HD
REGULATION OF SPHINGOMYELIN PATHWAY IN THE CORPUS LUTEUM$194,320
R01 · FY2001 · HD
REGULATION OF SPHINGOMYELIN PATHWAY IN THE CORPUS LUTEUM$173,035
R01 · FY2000 · HD
REGULATION OF SPHINGOMYELIN PATHWAY IN THE CORPUS LUTEUM$28,108
R01 · FY2000 · HD